Company registration number 11082391 (England and Wales)
VYTA HEALTH LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
VYTA HEALTH LIMITED
COMPANY INFORMATION
Directors
Mr W Brennand
Mrs C Bristow
Ms EL Kaplan
(Appointed 17 June 2025)
Company number
11082391
Registered office
3 Maclaren House
Skerne Road
Driffield
England
YO25 6PN
Auditor
BHP LLP
Mayesbrook House
Lawnswood Business Park
Redvers Close
Leeds
LS16 6QY
VYTA HEALTH LIMITED
CONTENTS
Page
Strategic report
1 - 2
Directors' report
3 - 4
Independent auditor's report
5 - 7
Group statement of comprehensive income
8
Group balance sheet
9 - 10
Company balance sheet
11
Group statement of changes in equity
12
Company statement of changes in equity
13
Group statement of cash flows
14
Notes to the financial statements
15 - 31
VYTA HEALTH LIMITED
STRATEGIC REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 1 -
The directors present the Strategic Report of Vyta Health Limited (the "Company") for the year ended 31 December 2024.
Review of the business
The directors are pleased to report a successful growth year for the Vyta Health Group and are confident that the group is in a strong position moving into the forthcoming year.
The principal business of the Group is the sale of vitamins and supplements in the UK and EU, through an omnichannel approach.
The Company continues to develop strong relationships with many brands which it partners with in order to bring their products to UK and EU markets and do this through a strong presence on Amazon stores, direct to consumer websites and a network of resellers.
Key drivers of the business include marketing performance and brand efficiency. We continue to make investments in people and processes in order to maximise both, and are investing a new ERP system and data reporting tool, in order to improve our data and reporting strategy.
Financial Review
The company has developed a comprehensive set of key performance indicators (KPIs) that are continually measured and reported throughout the organization. These are aligned with the overall objectives of the Company of continuing to develop strong brand relationships and strong channel performance.
Turnover has increased 10.5% in the year to £28.8m (FY23: £26.1m), this was driven by an increase in sales in the B2B channel which, due to its nature, has a lower margin per unit contribution, leading to a reduced EBITDA of 5.31% (FY23: 7.64%) during the same period. Liquidity remains strong, a decrease on prior year was due to repayment of bank loans and an equity restructure including existing shareholders.
Principal risks and uncertainties
The board and management continually assess the current state and future prospects of the company, in particular the context of risks and uncertainties which could potentially impact the business.
Revenue - The company operates an omnichannel approach which moves to diversify against potential revenue declines in any one area and partners with over 50 brands providing a stable platform to provide product.
Liquidity - 95% of revenues are generated online with payment made on order, while most product sales come with 30 day terms.
Foreign Exchange Risk – the company trades in GBP, EUR and USD and while there are opportunities for some natural hedges, the company also closely monitors exchange rates to minimize risk in fluctuations.
Compliance – the company closely monitors changes in regulations and standards across the UK and EU, any new products undergoing inspection before being listed for sale, and regular audits and monitoring at Board level.
Future Development
The long-term goal of the Company is to be the number 1 provider of vitamins and supplements in the UK and EU.
Through continuous improvement in Amazon and D2C channels as well as maintaining strong relationships with both brands and resellers we can continue to grow both the Company’s brand as well as those of our vendors.
VYTA HEALTH LIMITED
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 2 -
Mr W Brennand
Director
30 September 2025
VYTA HEALTH LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 3 -
The directors present their annual report and financial statements for the year ended 31 December 2024.
Principal activities
The principal activity of the group continued to be that of delivering and supplying health and wellbeing products. The principal activity of the company is a holding company.
Results and dividends
The results for the year are set out on page 8.
No ordinary dividends were paid. The directors do not recommend payment of a further dividend.
Directors
The directors who held office during the year and up to the date of signature of the financial statements were as follows:
Mr W Brennand
Mrs C Bristow
Mr A Hirst
(Resigned 31 July 2025)
Ms EL Kaplan
(Appointed 17 June 2025)
Auditor
In accordance with the company's articles, a resolution proposing that BHP LLP be reappointed as auditor of the group will be put at a General Meeting.
Statement of directors' responsibilities
The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulations.
Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the group and company, and of the profit or loss of the group for that period. In preparing these financial statements, the directors are required to:
select suitable accounting policies and then apply them consistently;
make judgements and accounting estimates that are reasonable and prudent;
state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the group and company will continue in business.
The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the group’s and company’s transactions and disclose with reasonable accuracy at any time the financial position of the group and company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the group and company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
Statement of disclosure to auditor
So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the auditor of the company is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the auditor of the company is aware of that information.
VYTA HEALTH LIMITED
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 4 -
Medium-sized companies exemption
This report has been prepared in accordance with the provisions applicable to companies entitled to the medium-sized companies exemption.
On behalf of the board
Mr W Brennand
Director
30 September 2025
VYTA HEALTH LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF VYTA HEALTH LIMITED
- 5 -
Opinion
We have audited the financial statements of Vyta Health Limited (the 'parent company') and its subsidiaries (the 'group') for the year ended 31 December 2024 which comprise the group statement of comprehensive income, the group balance sheet, the company balance sheet, the group statement of changes in equity, the company statement of changes in equity, the group statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).
In our opinion the financial statements:
give a true and fair view of the state of the group's and the parent company's affairs as at 31 December 2024 and of the group's profit for the year then ended;
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
have been prepared in accordance with the requirements of the Companies Act 2006.
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.
The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of our audit:
The information given in the strategic report and the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
The strategic report and the directors' report have been prepared in accordance with applicable legal requirements.
VYTA HEALTH LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF VYTA HEALTH LIMITED
- 6 -
Matters on which we are required to report by exception
In the light of the knowledge and understanding of the group and the parent company and their environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report.
We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:
adequate accounting records have not been kept by the parent company, or returns adequate for our audit have not been received from branches not visited by us; or
the parent company financial statements are not in agreement with the accounting records and returns; or
certain disclosures of directors' remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit.
Responsibilities of directors
As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the parent company or to cease operations, or have no realistic alternative but to do so.
Auditor's responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:
the engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations;
we identified the laws and regulations applicable to the Group through discussions with directors and other management, and from our commercial knowledge and experience of the trade;
we focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the Group;
we assessed the extent of compliance with the laws and regulations considered above through making enquiries of management; and
identified laws and regulations were communicated within the audit team regularly and the team remained alert to instances of non-compliance throughout the audit.
We assessed the susceptibility of the group's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:
making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud; and
considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations.
VYTA HEALTH LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF VYTA HEALTH LIMITED
- 7 -
To address the risks of fraud through management bias and override of controls, we:
performed analytical procedures to identify any unusual or unexpected relationships;
tested journal entries to identify unusual transactions;
assessed whether judgements and assumptions made in determining the accounting estimates were indicative of potential bias; and
investigated the rationale behind significant or unusual transactions.
In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:
agreeing financial statement disclosures to underlying supporting documentation;
enquiring of management as to actual and potential litigation and claims; and
discussions with senior management regarding relevant regulations and reviewing the group's legal and professional fees.
There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from the financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence.
A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.
This report is made solely to the company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company’s members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company’s members as a body, for our audit work, for this report, or for the opinions we have formed.
Chris Neale (Senior Statutory Auditor)
For and on behalf of BHP LLP, Statutory Auditor
Chartered Accountants
Mayesbrook House
Lawnswood Business Park
Redvers Close
Leeds
LS16 6QY
30 September 2025
VYTA HEALTH LIMITED
GROUP STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 DECEMBER 2024
- 8 -
2024
2023
Notes
£
£
Turnover
3
28,830,427
26,083,073
Cost of sales
(22,942,043)
(19,890,775)
Gross profit
5,888,384
6,192,298
Administrative expenses
(4,757,294)
(4,234,710)
Other operating income
-
12,083
Operating profit
4
1,131,090
1,969,671
Interest receivable and similar income
7
12,609
29,988
Interest payable and similar expenses
8
(152,690)
(184,274)
Profit before taxation
991,009
1,815,385
Tax on profit
9
(370,078)
(485,916)
Profit for the financial year
620,931
1,329,469
Other comprehensive income
Currency translation loss taken to retained earnings
(360,197)
(66,526)
Total comprehensive income for the year
260,734
1,262,943
Profit for the financial year is attributable to:
- Owners of the parent company
467,966
1,104,096
- Non-controlling interests
152,965
225,373
620,931
1,329,469
Total comprehensive income for the year is attributable to:
- Owners of the parent company
195,437
1,053,363
- Non-controlling interests
65,297
209,580
260,734
1,262,943
VYTA HEALTH LIMITED
GROUP BALANCE SHEET
AS AT
31 DECEMBER 2024
31 December 2024
- 9 -
2024
2023
Notes
£
£
£
£
Fixed assets
Goodwill
10
483,506
1,006,789
Other intangible assets
10
204,138
110,653
Total intangible assets
687,644
1,117,442
Tangible assets
11
146,077
141,577
833,721
1,259,019
Current assets
Stocks
14
3,408,054
3,686,772
Debtors
15
1,151,433
601,198
Cash at bank and in hand
896,917
1,456,942
5,456,404
5,744,912
Creditors: amounts falling due within one year
16
(3,531,112)
(3,380,651)
Net current assets
1,925,292
2,364,261
Total assets less current liabilities
2,759,013
3,623,280
Creditors: amounts falling due after more than one year
17
(873,328)
(598,364)
Provisions for liabilities
Deferred tax liability
19
31,789
26,486
(31,789)
(26,486)
Net assets
1,853,896
2,998,430
Capital and reserves
Called up share capital
21
99
99
Profit and loss reserves
1,443,236
1,701,395
Equity attributable to owners of the parent company
1,443,335
1,701,494
Non-controlling interests
410,561
1,296,936
Total equity
1,853,896
2,998,430
VYTA HEALTH LIMITED
GROUP BALANCE SHEET (CONTINUED)
AS AT
31 DECEMBER 2024
31 December 2024
- 10 -
These financial statements have been prepared in accordance with the provisions relating to medium-sized groups.
The financial statements were approved by the board of directors and authorised for issue on 30 September 2025 and are signed on its behalf by:
30 September 2025
Mr W Brennand
Director
Company registration number 11082391 (England and Wales)
VYTA HEALTH LIMITED
COMPANY BALANCE SHEET
AS AT 31 DECEMBER 2024
31 December 2024
- 11 -
2024
2023
Notes
£
£
£
£
Fixed assets
Investments
12
485,434
485,434
485,434
485,434
Current assets
Debtors
15
49,747
49,747
Cash at bank and in hand
21,066
42,003
70,813
91,750
Creditors: amounts falling due within one year
16
(391,804)
(422,604)
Net current liabilities
(320,991)
(330,854)
Total assets less current liabilities
164,443
154,580
Creditors: amounts falling due after more than one year
17
(150,000)
(150,000)
Net assets
14,443
4,580
Capital and reserves
Called up share capital
21
99
99
Profit and loss reserves
14,344
4,481
Total equity
14,443
4,580
As permitted by s408 Companies Act 2006, the company has not presented its own profit and loss account and related notes. The company's profit for the year was £9,863 (2023 - £3,410 profit).
These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.
The financial statements were approved by the board of directors and authorised for issue on 30 September 2025 and are signed on its behalf by:
30 September 2025
Mr W Brennand
Director
Company registration number 11082391 (England and Wales)
VYTA HEALTH LIMITED
GROUP STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2024
- 12 -
Share capital
Profit and loss reserves
Total controlling interest
Non-controlling interest
Total
£
£
£
£
£
Balance at 1 January 2023
99
648,032
648,131
1,087,356
1,735,487
Year ended 31 December 2023:
Profit for the year
-
1,104,096
1,104,096
225,373
1,329,469
Other comprehensive income:
Currency translation differences
-
(50,733)
(50,733)
(15,793)
(66,526)
Total comprehensive income
-
1,053,363
1,053,363
209,580
1,262,943
Balance at 31 December 2023
99
1,701,395
1,701,494
1,296,936
2,998,430
Year ended 31 December 2024:
Profit for the year
-
467,966
467,966
152,965
620,931
Other comprehensive income:
Currency translation differences
-
(272,529)
(272,529)
(87,668)
(360,197)
Total comprehensive income
-
195,437
195,437
65,297
260,734
Purchase of shares in subsidiary from non-controlling interest
-
(453,596)
(453,596)
(951,672)
(1,405,268)
Balance at 31 December 2024
99
1,443,236
1,443,335
410,561
1,853,896
VYTA HEALTH LIMITED
COMPANY STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2024
- 13 -
Share capital
Profit and loss reserves
Total
£
£
£
Balance at 1 January 2023
99
1,071
1,170
Year ended 31 December 2023:
Profit and total comprehensive income for the year
-
3,410
3,410
Balance at 31 December 2023
99
4,481
4,580
Year ended 31 December 2024:
Profit and total comprehensive income
-
9,863
9,863
Balance at 31 December 2024
99
14,344
14,443
VYTA HEALTH LIMITED
GROUP STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 14 -
2024
2023
Notes
£
£
£
£
Cash flows from operating activities
Cash generated from operations
24
1,178,308
1,739,053
Income taxes paid
(450,485)
(443,122)
Net cash inflow from operating activities
727,823
1,295,931
Investing activities
Purchase of intangible assets
(118,740)
-
Purchase of tangible fixed assets
(56,245)
(80,769)
Interest received
12,609
18,578
Dividends received from related parties
11,410
Net cash used in investing activities
(162,376)
(50,781)
Financing activities
Repayment of bank loans
(538,671)
(720,562)
Purchase of shares in subsidiary from non-controlling interest
(371,869)
-
Interest paid
(152,690)
(184,274)
Net cash used in financing activities
(1,063,230)
(904,836)
Net (decrease)/increase in cash and cash equivalents
(497,783)
340,314
Cash and cash equivalents at beginning of year
1,456,942
1,140,325
Effect of foreign exchange rates
(62,242)
(23,697)
Cash and cash equivalents at end of year
896,917
1,456,942
VYTA HEALTH LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 15 -
1
Accounting policies
Company information
Vyta Health Limited (“the company”) is a private limited company domiciled and incorporated in England and Wales. The registered office is 3 Maclaren House, Skerne Road, Driffield, England, YO25 6PN.
The group consists of Vyta Health Limited and all of its subsidiaries.
1.1
Accounting convention
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
The company is a qualifying entity for the purposes of FRS 102, being a member of a group where the parent of that group prepares publicly available consolidated financial statements, including this company, which are intended to give a true and fair view of the assets, liabilities, financial position and profit or loss of the group. The company has therefore taken advantage of exemptions from the following disclosure requirements for parent company information presented within the consolidated financial statements:
Section 7 ‘Statement of Cash Flows’: Presentation of a statement of cash flow and related notes and disclosures;
Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instrument Issues: Interest income/expense and net gains/losses for financial instruments not measured at fair value; basis of determining fair values; details of collateral, loan defaults or breaches, details of hedges, hedging fair value changes recognised in profit or loss and in other comprehensive income;
Section 26 ‘Share based Payment’: Share-based payment expense charged to profit or loss, reconciliation of opening and closing number and weighted average exercise price of share options, how the fair value of options granted was measured, measurement and carrying amount of liabilities for cash-settled share-based payments, explanation of modifications to arrangements;
Section 33 ‘Related Party Disclosures’: Compensation for key management personnel.
1.2
Business combinations
In the parent company financial statements, the cost of a business combination is the fair value at the acquisition date of the assets given, equity instruments issued and liabilities incurred or assumed, plus costs directly attributable to the business combination. The excess of the cost of a business combination over the fair value of the identifiable assets, liabilities and contingent liabilities acquired is recognised as goodwill. The cost of the combination includes the estimated amount of contingent consideration that is probable and can be measured reliably, and is adjusted for changes in contingent consideration after the acquisition date. Provisional fair values recognised for business combinations in previous periods are adjusted retrospectively for final fair values determined in the 12 months following the acquisition date. Investments in subsidiaries, joint ventures and associates are accounted for at cost less impairment.
Deferred tax is recognised on differences between the value of assets (other than goodwill) and liabilities recognised in a business combination accounted for using the purchase method and the amounts that can be deducted or assessed for tax, considering the manner in which the carrying amount of the asset or liability is expected to be recovered or settled. The deferred tax recognised is adjusted against goodwill or negative goodwill.
VYTA HEALTH LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 16 -
1.3
Basis of consolidation
The consolidated group financial statements consist of the financial statements of the parent company Vyta Health Limited (formally Bigvits Limited) together with all entities controlled by the parent company (its subsidiaries) and the group’s share of its interests in joint ventures and associates.
All financial statements are made up to 31 December 2024. Where necessary, adjustments are made to the financial statements of subsidiaries to bring the accounting policies used into line with those used by other members of the group.
All intra-group transactions, balances and unrealised gains on transactions between group companies are eliminated on consolidation. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.
Subsidiaries are consolidated in the group’s financial statements from the date that control commences until the date that control ceases.
Entities in which the group holds an interest and which are jointly controlled by the group and one or more other venturers under a contractual arrangement are treated as joint ventures. Entities other than subsidiary undertakings or joint ventures, in which the group has a participating interest and over whose operating and financial policies the group exercises a significant influence, are treated as associates.
Non-controlling interest represents the minority share in subsidiaries controlled and consolidated into the group. An adjustment is made each year to account for the minority shareholders proportion of results in the respective subsidiaries.
1.4
Going concern
Vyta Health Limited is the holding company of trading entities Trade Vits Limited, By Nature BV and Big Vits Holding Company(collectively the “Group”). Management has assessed going concern on a wider group basis as follows.
The company has set a bold trajectory for future growth, beginning with the rollout of a new Enterprise Resource Planning (ERP) system, alongside enhanced tools for data reporting and inventory forecasting. These initiatives are foundational to improving visibility, control, and agility across the business.
Our strategic focus for FY25 centres on strengthening unit economics and operational efficiency. This includes targeted investment in our people, processes, and governance to ensure we can continue scaling at pace while maintaining financial discipline.
Despite increasing competition within the sector, our strong relationships with key brand partners, coupled with our deep market expertise, position us well to defend and grow our market share.
In the event of any future cash flow pressures, we have identified clear levers to protect liquidity—namely, optimising inventory levels and expanding access to working capital facilities.
The directors consider there are no material uncertainties that may cast significant doubt on the Group’s ability to continue to operate as a going concern. There is reasonable expectation that the Group have adequate resources to continue in operational existence for the foreseeable future.
In 2024, a wholly owned group company, BigVits Holdco BV purchased an additional 18% of shares in By Nature Holdings BV, from a shareholder, for consideration of €1,850,000. An initial cash sum of €350,000 was paid for the shares and the remaining balance was facilitated by a loan from the shareholder to BigVits Holdco BV payable quarterly, over 3 years, which is included within other creditors. BigVits Holdco BV now owns 88% of By Nature Holdings BV, with plans to increase this to 100% in 2025.
VYTA HEALTH LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 17 -
1.5
Turnover
Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.
Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.
1.6
Intangible fixed assets - goodwill
Goodwill represents the excess of the cost of acquisition of a business over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 5 years.
For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit.
1.7
Intangible fixed assets other than goodwill
Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.
Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.
Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Software
5 or 10 years straightline
Patents & licences
5 or 10 years straightline
1.8
Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Plant and equipment
25% straight line
Fixtures and fittings
25% straight line
Computers
3 years straight line
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the profit and loss account.
VYTA HEALTH LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 18 -
1.9
Fixed asset investments
Equity investments are measured at fair value through profit or loss, except for those equity investments that are not publicly traded and whose fair value cannot otherwise be measured reliably, which are recognised at cost less impairment until a reliable measure of fair value becomes available.
In the parent company financial statements, investments in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses.
A subsidiary is an entity controlled by the group. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.
1.10
Impairment of fixed assets
At each reporting period end date, the group reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.
The carrying amount of the investments accounted for using the equity method is tested for impairment as a single asset. Any goodwill included in the carrying amount of the investment is not tested separately for impairment.
Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.
If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.
Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.
1.11
Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.
At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.
1.12
Cash and cash equivalents
Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.
VYTA HEALTH LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 19 -
1.13
Financial instruments
The group has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the group's balance sheet when the group becomes party to the contractual provisions of the instrument.
Financial assets and liabilities are offset and the net amounts presented in the financial statements when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
Other financial assets
Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.
Impairment of financial assets
Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.
Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.
If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.
Derecognition of financial assets
Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the group transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.
Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the group after deducting all of its liabilities.
VYTA HEALTH LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 20 -
Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
Other financial liabilities
Derivatives, including interest rate swaps and forward foreign exchange contracts, are not basic financial instruments. Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or finance income as appropriate, unless hedge accounting is applied and the hedge is a cash flow hedge.
Debt instruments that do not meet the conditions in FRS 102 paragraph 11.9 are subsequently measured at fair value through profit or loss. Debt instruments may be designated as being measured at fair value through profit or loss to eliminate or reduce an accounting mismatch or if the instruments are measured and their performance evaluated on a fair value basis in accordance with a documented risk management or investment strategy.
Derecognition of financial liabilities
Financial liabilities are derecognised when the group's contractual obligations expire or are discharged or cancelled.
1.14
Equity instruments
Equity instruments issued by the group are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the group.
1.15
Taxation
The tax expense represents the sum of the tax currently payable and deferred tax.
Current tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The group’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
VYTA HEALTH LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 21 -
Deferred tax
Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.
The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset if, and only if, there is a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.
1.16
Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.
Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.
1.17
Retirement benefits
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
1.18
Foreign exchange
Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.
2
Judgements and key sources of estimation uncertainty
In the application of the group’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.
Key sources of estimation uncertainty
The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows.
Stock provisioning
The Directors’ have determined a stock provision taking into account the age of the stock, future estimated usage, and stocks likely realisable value. Refer to note 13 for further details.
VYTA HEALTH LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 22 -
3
Turnover and other revenue
2024
2023
£
£
Turnover analysed by class of business
Health and wellbeing products
28,830,427
26,083,073
2024
2023
£
£
Turnover analysed by geographical market
United Kingdom
10,722,364
6,170,627
Europe
17,857,469
19,726,015
Rest of World
250,594
186,431
28,830,427
26,083,073
2024
2023
£
£
Other revenue
Interest income
12,609
30,188
4
Operating profit
2024
2023
£
£
Operating profit for the year is stated after charging/(crediting):
Exchange gains
(110,476)
(13,633)
Fees payable to the group's auditor for the audit of the group's financial statements
24,169
26,872
Depreciation of owned tangible fixed assets
46,639
42,240
Amortisation of intangible assets
462,369
483,648
5
Employees
The average monthly number of persons (including directors) employed by the group and company during the year was:
Group
Company
2024
2023
2024
2023
Number
Number
Number
Number
49
38
3
3
VYTA HEALTH LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
5
Employees
(Continued)
- 23 -
Their aggregate remuneration comprised:
Group
Company
2024
2023
2024
2023
£
£
£
£
Wages and salaries
1,999,109
1,711,254
Social security costs
283,925
144,161
-
-
Pension costs
14,190
11,744
2,297,224
1,867,159
6
Directors' remuneration
2024
2023
£
£
Remuneration for qualifying services
206,460
192,150
Company pension contributions to defined contribution schemes
3,761
3,693
210,221
195,843
Remuneration disclosed above includes the following amounts paid to the highest paid director:
2024
2023
£
£
Remuneration for qualifying services
103,960
-
Company pension contributions to defined contribution schemes
1,321
-
7
Interest receivable and similar income
2024
2023
£
£
Interest income
Interest on bank deposits
10,982
18,578
Interest receivable from group companies
1,627
11,610
Total income
12,609
30,188
8
Interest payable and similar expenses
2024
2023
£
£
Other interest on financial liabilities
71,726
41,473
Other interest
80,964
142,801
Total finance costs
152,690
184,274
VYTA HEALTH LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 24 -
9
Taxation
2024
2023
£
£
Current tax
Corporation tax on profits for the current period
362,934
480,233
Adjustments in respect of prior periods
562
1,485
Other taxes
1,279
3,266
Total current tax
364,775
484,984
Deferred tax
Origination and reversal of timing differences
5,303
934
Total tax charge
370,078
485,916
The actual charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:
2024
2023
£
£
Profit before taxation
991,009
1,815,385
Expected tax charge based on the standard rate of corporation tax in the UK of 25.00% (2023: 23.52%)
247,752
426,979
Tax effect of expenses that are not deductible in determining taxable profit
7,940
(80,132)
Change in unrecognised deferred tax assets
(509)
4,735
Adjustments in respect of prior years
562
1,485
Effect of change in corporation tax rate
-
(371)
Permanent capital allowances in excess of depreciation
4,242
Amortisation on assets not qualifying for tax allowances
109,729
108,193
Deferred tax adjustments in respect of prior years
(750)
Tax at marginal rate
(477)
Overseas subsidiaries not subject to UK corporation tax
3,993
21,535
Other differences
1,088
Taxation charge
370,078
485,916
VYTA HEALTH LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 25 -
10
Intangible fixed assets
Group
Goodwill
Software
Patents & licences
Total
£
£
£
£
Cost
At 1 January 2024
2,300,031
169,099
53,060
2,522,190
Additions
118,740
118,740
Exchange adjustments
(105,459)
(2,467)
(107,926)
At 31 December 2024
2,194,572
287,839
50,593
2,533,004
Amortisation and impairment
At 1 January 2024
1,293,242
99,866
11,640
1,404,748
Amortisation charged for the year
438,916
18,270
5,183
462,369
Exchange adjustments
(21,092)
(665)
(21,757)
At 31 December 2024
1,711,066
118,136
16,158
1,845,360
Carrying amount
At 31 December 2024
483,506
169,703
34,435
687,644
At 31 December 2023
1,006,789
69,233
41,420
1,117,442
The company had no intangible fixed assets at 31 December 2024 or 31 December 2023.
VYTA HEALTH LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 26 -
11
Tangible fixed assets
Group
Plant and equipment
Fixtures and fittings
Computers
Total
£
£
£
£
Cost
At 1 January 2024
167,367
54,078
16,575
238,020
Additions
20,646
22,757
12,842
56,245
Exchange adjustments
3,038
3,038
At 31 December 2024
191,051
76,835
29,417
297,303
Depreciation and impairment
At 1 January 2024
51,683
32,846
11,914
96,443
Depreciation charged in the year
32,262
10,049
4,328
46,639
Exchange adjustments
8,144
8,144
At 31 December 2024
92,089
42,895
16,242
151,226
Carrying amount
At 31 December 2024
98,962
33,940
13,175
146,077
At 31 December 2023
115,684
21,232
4,661
141,577
The company had no tangible fixed assets at 31 December 2024 or 31 December 2023.
12
Fixed asset investments
Group
Company
2024
2023
2024
2023
Notes
£
£
£
£
Investments in subsidiaries
13
485,434
485,434
Movements in fixed asset investments
Company
Shares in subsidiaries
£
Cost or valuation
At 1 January 2024 and 31 December 2024
485,434
Carrying amount
At 31 December 2024
485,434
At 31 December 2023
485,434
VYTA HEALTH LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 27 -
13
Subsidiaries
Details of the company's subsidiaries at 31 December 2024 are as follows:
Name of undertaking
Registered office
Class of
% Held
shares held
Direct
Indirect
Tradevits Limited
3 Maclaren House, Skerne Road, Driffield, England, YO25 6PN.
Ordinary
100.00
-
Retailvits Limited
3 Maclaren House, Skerne Road, Driffield, England, YO25 6PN.
Ordinary
100.00
-
Bigvits Group Limited
3 Maclaren House, Skerne Road, Driffield, England, YO25 6PN.
Ordinary
100.00
-
By Nature Holdings B.V.
Vogt 21, 6422 RK, Heerlen, Netherlands
Ordinary
0
88.00
By Nature B.V.
Vogt 21, 6422 RK, Heerlen, Netherlands
Ordinary
0
100.00
Bigvits Holdco B.V.
Vogt 21, 6422 RK, Heerlen, Netherlands
Ordinary
100.00
-
During the year, the group acquired an additional 18% shareholding in By Nature Holdings BV for €1,850,000.
14
Stocks
Group
Company
2024
2023
2024
2023
£
£
£
£
Finished goods and goods for resale
3,408,054
3,686,772
The amounts presented above are net of stock provisions of £252,058 (2023: £79,268).
15
Debtors
Group
Company
2024
2023
2024
2023
Amounts falling due within one year:
£
£
£
£
Trade debtors
379,660
220,503
Amounts owed by group undertakings
-
-
49,648
49,648
Other debtors
732,619
261,784
99
99
Prepayments and accrued income
39,154
118,911
1,151,433
601,198
49,747
49,747
Amounts owed by group undertakings are provided interest free and are repayable on demand.
VYTA HEALTH LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 28 -
16
Creditors: amounts falling due within one year
Group
Company
2024
2023
2024
2023
Notes
£
£
£
£
Bank loans
18
592,012
682,319
Trade creditors
1,216,028
1,147,541
Amounts owed to group undertakings
391,804
421,804
Corporation tax payable
228,967
314,677
800
Other taxation and social security
389,060
553,500
-
-
Other creditors
700,835
389,424
Accruals and deferred income
404,210
293,190
3,531,112
3,380,651
391,804
422,604
Amounts owed to group undertakings are provided interest free and are repayable on demand.
17
Creditors: amounts falling due after more than one year
Group
Company
2024
2023
2024
2023
Notes
£
£
£
£
Bank loans and overdrafts
18
448,364
Other creditors
873,328
150,000
150,000
150,000
873,328
598,364
150,000
150,000
18
Loans and overdrafts
Group
Company
2024
2023
2024
2023
£
£
£
£
Bank loans
592,012
1,130,683
Payable within one year
592,012
682,319
Payable after one year
448,364
592,012
1,130,683
Included within bank loans is a secured loan which is repayable in quarterly instalments and is subject to interest at 8.75%.
VYTA HEALTH LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 29 -
19
Deferred taxation
The following are the major deferred tax liabilities and assets recognised by the group and company, and movements thereon:
Liabilities
Liabilities
2024
2023
Group
£
£
Timing differences
31,789
26,486
The company has no deferred tax assets or liabilities.
Group
Company
2024
2024
Movements in the year:
£
£
Liability at 1 January 2024
26,486
-
Charge to profit or loss
5,303
-
Liability at 31 December 2024
31,789
-
The deferred tax liability set out above is expected to reverse within 12 months and relates to accelerated capital allowances that are expected to mature within the same period.
20
Retirement benefit schemes
2024
2023
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
14,190
11,744
A defined contribution pension scheme is operated for all qualifying employees. The assets of the scheme are held separately from those of the group in an independently administered fund.
21
Share capital
Group and company
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
99
99
99
99
VYTA HEALTH LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 30 -
22
Operating lease commitments
At the reporting end date the group had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:
Group
Company
2024
2023
2024
2023
£
£
£
£
Within one year
82,384
63,782
-
-
Between two and five years
202,394
67,232
-
-
284,778
131,014
-
-
23
Directors' transactions
The following amounts are due to directors of the company at the year end. The balance are not repayable within 12 months.
Description
% Rate
Opening balance
Interest charged
Amounts repaid
Closing balance
£
£
£
£
Directors loan
10.00
50,000
4,011
(4,011)
50,000
Directors loan
10.00
50,000
4,011
(4,011)
50,000
100,000
8,022
(8,022)
100,000
24
Cash generated from group operations
2024
2023
£
£
Profit for the year after tax
620,931
1,329,469
Adjustments for:
Taxation charged
370,078
485,916
Finance costs
152,690
184,274
Investment income
(12,609)
(29,988)
Amortisation and impairment of intangible assets
462,369
483,648
Depreciation and impairment of tangible fixed assets
46,639
42,240
Movements in working capital:
Decrease/(increase) in stocks
278,718
(1,088,786)
Increase in debtors
(550,235)
(187,810)
(Decrease)/increase in creditors
(190,273)
520,090
Cash generated from operations
1,178,308
1,739,053
VYTA HEALTH LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 31 -
25
Analysis of changes in net funds - group
1 January 2024
Cash flows
Exchange rate movements
31 December 2024
£
£
£
£
Cash at bank and in hand
1,456,942
(497,783)
(62,242)
896,917
Borrowings excluding overdrafts
(1,130,683)
538,671
-
(592,012)
326,259
40,888
(62,242)
304,905
2024-12-312024-01-01falsefalseCCH SoftwareCCH Accounts Production 2025.200Mr W BrennandMrs C BristowMr A HirstMs EL Kaplanfalse11082391bus:Consolidated2024-01-012024-12-31110823912024-01-012024-12-3111082391bus:Director12024-01-012024-12-3111082391bus:Director22024-01-012024-12-3111082391bus:Director42024-01-012024-12-3111082391bus:Director32024-01-012024-12-3111082391bus:RegisteredOffice2024-01-012024-12-31110823912024-12-3111082391bus:Consolidated2024-12-3111082391bus:Consolidated2023-01-012023-12-31110823912023-01-012023-12-3111082391core:RetainedEarningsAccumulatedLossesbus:Consolidated2024-01-012024-12-3111082391core:RetainedEarningsAccumulatedLossesbus:Consolidated2023-01-012023-12-3111082391core:Goodwillbus:Consolidated2024-12-3111082391core:Goodwillbus:Consolidated2023-12-3111082391core:IntangibleAssetsOtherThanGoodwillbus:Consolidated2024-12-3111082391core:IntangibleAssetsOtherThanGoodwillbus:Consolidated2023-12-3111082391bus:Consolidated2023-12-3111082391core:ComputerSoftwarebus:Consolidated2024-12-3111082391core:PatentsTrademarksLicencesConcessionsSimilarbus:Consolidated2024-12-3111082391core:ComputerSoftwarebus:Consolidated2023-12-3111082391core:PatentsTrademarksLicencesConcessionsSimilarbus:Consolidated2023-12-3111082391core:PlantMachinerybus:Consolidated2024-12-3111082391core:FurnitureFittingsbus:Consolidated2024-12-3111082391core:ComputerEquipmentbus:Consolidated2024-12-3111082391core:PlantMachinerybus:Consolidated2023-12-3111082391core:FurnitureFittingsbus:Consolidated2023-12-3111082391core:ComputerEquipmentbus:Consolidated2023-12-31110823912023-12-3111082391core:ShareCapitalbus:Consolidated2024-12-3111082391core:ShareCapitalbus:Consolidated2023-12-3111082391core:RetainedEarningsAccumulatedLossesbus:Consolidated2024-12-3111082391core:RetainedEarningsAccumulatedLossesbus:Consolidated2023-12-3111082391core:Non-controllingInterestsbus:Consolidated2024-12-3111082391core:Non-controllingInterestsbus:Consolidated2023-12-3111082391core:ShareCapital2024-12-3111082391core:ShareCapital2023-12-3111082391core:RetainedEarningsAccumulatedLosses2024-12-3111082391core:RetainedEarningsAccumulatedLosses2023-12-3111082391core:ShareCapitalbus:Consolidated2022-12-31110823912022-12-3111082391core:ShareCapital2022-12-3111082391core:RetainedEarningsAccumulatedLosses2022-12-3111082391bus:Consolidated2022-12-3111082391core:Goodwill2024-01-012024-12-3111082391core:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3111082391core:ComputerSoftware2024-01-012024-12-3111082391core:PatentsTrademarksLicencesConcessionsSimilar2024-01-012024-12-3111082391core:PlantMachinery2024-01-012024-12-3111082391core:FurnitureFittings2024-01-012024-12-3111082391core:ComputerEquipment2024-01-012024-12-3111082391core:UKTaxbus:Consolidated2024-01-012024-12-3111082391core:UKTaxbus:Consolidated2023-01-012023-12-3111082391bus:Consolidated12024-01-012024-12-3111082391bus:Consolidated12023-01-012023-12-3111082391bus:Consolidated22024-01-012024-12-3111082391bus:Consolidated22023-01-012023-12-3111082391bus:Consolidated32024-01-012024-12-3111082391bus:Consolidated32023-01-012023-12-3111082391bus:Consolidated42024-01-012024-12-3111082391bus:Consolidated42023-01-012023-12-3111082391core:Goodwillbus:Consolidated2023-12-3111082391core:ComputerSoftwarebus:Consolidated2023-12-3111082391core:PatentsTrademarksLicencesConcessionsSimilarbus:Consolidated2023-12-3111082391bus:Consolidated2023-12-3111082391core:Goodwillcore:ExternallyAcquiredIntangibleAssetsbus:Consolidated2024-01-012024-12-3111082391core:ComputerSoftwarecore:ExternallyAcquiredIntangibleAssetsbus:Consolidated2024-01-012024-12-3111082391core:PatentsTrademarksLicencesConcessionsSimilarcore:ExternallyAcquiredIntangibleAssetsbus:Consolidated2024-01-012024-12-3111082391core:ExternallyAcquiredIntangibleAssetsbus:Consolidated2024-01-012024-12-3111082391core:Goodwillbus:Consolidated2024-01-012024-12-3111082391core:ComputerSoftwarebus:Consolidated2024-01-012024-12-3111082391core:PatentsTrademarksLicencesConcessionsSimilarbus:Consolidated2024-01-012024-12-3111082391core:PlantMachinerybus:Consolidated2023-12-3111082391core:FurnitureFittingsbus:Consolidated2023-12-3111082391core:ComputerEquipmentbus:Consolidated2023-12-3111082391core:PlantMachinerybus:Consolidated2024-01-012024-12-3111082391core:FurnitureFittingsbus:Consolidated2024-01-012024-12-3111082391core:ComputerEquipmentbus:Consolidated2024-01-012024-12-3111082391core:Subsidiary12024-01-012024-12-3111082391core:Subsidiary22024-01-012024-12-3111082391core:Subsidiary32024-01-012024-12-3111082391core:Subsidiary42024-01-012024-12-3111082391core:Subsidiary52024-01-012024-12-3111082391core:Subsidiary62024-01-012024-12-3111082391core:Subsidiary112024-01-012024-12-3111082391core:Subsidiary222024-01-012024-12-3111082391core:Subsidiary332024-01-012024-12-3111082391core:Subsidiary442024-01-012024-12-3111082391core:Subsidiary552024-01-012024-12-3111082391core:Subsidiary662024-01-012024-12-3111082391core:CurrentFinancialInstruments2024-12-3111082391core:CurrentFinancialInstruments2023-12-3111082391core:CurrentFinancialInstrumentsbus:Consolidated2024-12-3111082391core:CurrentFinancialInstrumentsbus:Consolidated2023-12-3111082391core:WithinOneYearbus:Consolidated2024-12-3111082391core:WithinOneYearbus:Consolidated2023-12-3111082391core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3111082391core:CurrentFinancialInstrumentscore:WithinOneYear2023-12-3111082391core:Non-currentFinancialInstrumentscore:AfterOneYearbus:Consolidated2024-12-3111082391core:Non-currentFinancialInstrumentscore:AfterOneYearbus:Consolidated2023-12-3111082391core:Non-currentFinancialInstrumentscore:AfterOneYear2024-12-3111082391core:Non-currentFinancialInstrumentscore:AfterOneYear2023-12-3111082391core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2024-12-3111082391core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2023-12-3111082391core:Non-currentFinancialInstrumentscore:AfterOneYearbus:Consolidated12024-12-3111082391core:Non-currentFinancialInstrumentscore:AfterOneYearbus:Consolidated12023-12-3111082391core:Non-currentFinancialInstrumentscore:AfterOneYear22024-12-3111082391core:Non-currentFinancialInstrumentscore:AfterOneYear22023-12-3111082391bus:PrivateLimitedCompanyLtd2024-01-012024-12-3111082391bus:FRS1022024-01-012024-12-3111082391bus:Audited2024-01-012024-12-3111082391bus:ConsolidatedGroupCompanyAccounts2024-01-012024-12-3111082391bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP